16,120,125 It represented selleck products the first experimentally based approach to novel treatment of acute migraine attacks.126

Sumatriptan proved to be a highly effective (at least subcutaneously) and well-tolerated drug for the treatment of migraine attacks, and it was hailed as a medical breakthrough. The research was concentrated on the possible role of 5-hydroxytryptamine (serotonin) in migraine therapy as mentioned above in the section on methysergide. In 2 open studies,127,128 intravenous serotonin (5-HT) was found effective in the treatment of migraine attacks, albeit with so many adverse events that its therapeutic use would be impracticable. The research team in England set out trying to find the 5-HT receptor type responsible for 5-HT’s beneficial effect. Saxena had found that methysergide had a selectively constrictor effect in the dog carotid bed and suggested that this was an “atypical” 5-HT receptor.129 As part of an investigation into the mode of action of antimigraine drugs, a study of the excitatory receptors for 5-HT was carried out in a range of isolated vascular preparations of dogs.66 Serotonin was an agonist that resulted in contraction of all vessels whereas methysergide was an agonist only in the femoral vein.66 It was hypothesized that this was an

unknown 5-HT receptor in the dog femoral vein. 5-hydroxaminotryptamine (5-CONH2T), a potent selective 5-HT agonist, had only a weak effect on rabbit isolated aorta, whereas 5-CONH2T was a potent agonist in dog saphenous vein.130 In this vein ketanserin, a 5-HT2 antagonist, Angiogenesis inhibitor did not antagonize the effect of 5-CONH2T. Thus, the receptor mediating contraction in the dog saphenous vein appeared to be “5-HT-like.”130 Sumatriptan, which was synthesized in 1984,126 appeared to have a selective effect on the dog saphenous 上海皓元 vein and was accepted for clinical development on the basis of its high degree of selectivity for vascular “5-HT1-like” receptors that mediate constriction.130 These receptors are largely localized on large intracranial blood vessels from a variety of species including man131-135

and sumatriptan causes contraction of these vessels via an action on the 5-HT-1B receptor.136 The triptans, including sumatriptan, are relatively cranioselective when compared the effect on coronary arteries.122,137 A possible central effect of the triptan is probably mediated by both 5-HT-1B and 5-HT-1D receptors and other 5-HT receptors.122 The effect of subcutaneous sumatriptan 6 mg was proved in 2 large placebo-controlled, in-clinic RCTs. Headache relief rates of 70%138 and 72%139 after 1 hour were shown. Subcutaneous sumatriptan has a reasonable well-defined dose-response, with 1 mg being the minimum effective dose and 6 mg being the optimum dose with no gain by increasing to 8 mg.138-141 Oral sumatriptan became available and has been the standard triptan, being compared with all new oral triptans and other nontriptans drugs.